Vanguard Global Advisers’s ProKidney PROK Stock Holding History

Vanguard Global Advisers’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$69.5K	Hold	34,074	–	–	﹤0.01%	2946
2026 Q1	$61K	Buy	+34,074	New	+$72.3K	﹤0.01%	2937

Other funds holding PROK

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

AGP

Artia Global Partners Miami, Florida $542M AUM 206.64% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Global Advisers's PROK Position: Q2 2026 in Review

Vanguard Global Advisers held its ProKidney (PROK) position steady in Q2 2026 at 34,074 shares worth $69.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2946.

Vanguard Global Advisers first reported a position in PROK in Q1 2026 and has held it in 2 quarters since. 71 funds tracked by Wall St. Rank hold PROK as of Q2 2026.

Vanguard Global Advisers held 34,074 shares of ProKidney worth $69.5K as of Q2 2026.
Vanguard Global Advisers left its ProKidney share count unchanged in Q2 2026.
ProKidney made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2946 holding.
Vanguard Global Advisers first reported a position in ProKidney in Q1 2026 and has held it in 2 quarters since.
71 funds tracked by Wall St. Rank held ProKidney as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.